Advertised rate
From $93/month
Route
Injectable; provider page discusses subcutaneous and intramuscular use
Quantity
Not established by the reviewed starting-price offer
Shipping
Free delivery advertised
Membership
No membership fee advertised

What this listing actually buys

CoreAge Rx advertises NAD+ Injectable from $93 per month following an online clinical assessment. The listing is a starting offer for a prescription service, not a standardized retail box with a fully specified quantity in the headline. Before comparing the number with another provider, obtain the precise product and supply period associated with the prescription you are offered.

The provider page discusses more than one injection route. The actual route belongs in the clinician's instructions and pharmacy label; a consumer comparison should not choose it or convert one route into another. This review does not provide administration instructions.

Build the price around the order

Free shipping and no membership fees are advertised on the page. These remove two possible line items from the public offer, but they do not establish every possible cost for a particular patient. The final order should identify the medication amount, container count, included supplies and any recommended services charged separately.

If the individualized monthly charge really is $93 for twelve months, the simple medication scenario is $1,116. That arithmetic assumes an unchanged plan and does not turn the starting offer into a guaranteed annual price. Enter the actual quote into the worksheet before drawing comparisons with other subscriptions.

The vial information to request

Ask for the total milligrams, concentration, volume and dispensing pharmacy. These details serve different purposes: total amount describes the medication supplied, concentration describes its formulation, and volume identifies the container's liquid quantity. None independently establishes the length of treatment for an individual.

The pharmacy should also explain storage, the labeled beyond-use date and any shorter limit after first use. A container with material remaining does not necessarily represent usable future supply. This is why an apparently inexpensive larger vial cannot be evaluated only by dividing the price by the total amount.

Separate an energy claim from a measured result

The product is marketed for energy, recovery and cognitive support. We have not tested the preparation, and the listing does not give a reader a reliable personal timetable for benefit. NAD+'s biological role is a reason researchers study it, not a substitute for clinical outcomes with this specific prescription.

For context, the small published IV study cited in our evidence guide investigated NAD-related metabolites during an infusion. It did not test this at-home product or establish a predictable improvement in daily fatigue. Discuss what problem is being addressed and how the clinician would reassess the plan if it is not helping.

What to settle before the first shipment

Request the next billing date, the deadline to stop a refill and the procedure for a delivery or temperature concern. Also identify how to contact the clinical team if symptoms occur, rather than relying on a sales or shipping inbox to answer a medical question.

This product can enter a budget comparison once those details are written down. Until then, $93 remains an advertised floor with incomplete quantity information. CoreAge Rx's featured position is a commercial placement and does not mean this is the least expensive injection plan or that its formulation has demonstrated better results than the other listings.

Useful distinctions

  • Public monthly starting price
  • No separately advertised membership charge
  • Free shipping stated

Limitations to weigh

  • Vial quantity is not established by the headline
  • Actual prescription may cost more than the minimum
  • Compounded product is not FDA-approved

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. CoreAge Rx NAD+ Injectable Provider
  2. FDA: Compounding questions and answers Regulator
  3. Grant et al. 2019: Human plasma and urine metabolome during NAD+ IV infusion Clinical research